Jazz Pharmaceuticals plc financial data

Symbol
JAZZ on Nasdaq
Industry
Pharmaceutical Preparations
Location
Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin, Ireland
State of incorporation
Ireland
Fiscal year end
December 31
Former names
JAZZ PHARMACEUTICALS INC (to 1/18/2012)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 265 % -0.9%
Quick Ratio 39.7 % -34.9%
Return On Assets 4 % +455%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60.5M shares -3.98%
Common Stock, Shares, Outstanding 62.3M shares -1.52%
Entity Public Float 7.66B USD -19.6%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 61.4M shares -2.69%
Weighted Average Number of Shares Outstanding, Diluted 63.2M shares -11.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 3.99B USD +5.23%
Costs and Expenses 3.34B USD -7.15%
Operating Income (Loss) 648M USD +236%
Income Tax Expense (Benefit) -66.6M USD +64.4%
Net Income (Loss) Attributable to Parent 463M USD +479%
Earnings Per Share, Basic 7.45 USD/shares +526%
Earnings Per Share, Diluted 7.08 USD/shares +733%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.22B USD +66.1%
Accounts Receivable, after Allowance for Credit Loss, Current 724M USD +15.3%
Inventory, Net 539M USD -11.9%
Other Assets, Current 354M USD +14.1%
Assets, Current 4.39B USD +35.3%
Deferred Income Tax Assets, Net 583M USD +25.6%
Operating Lease, Right-of-Use Asset 77.2M USD +18.6%
Intangible Assets, Net (Excluding Goodwill) 5.14B USD -5.05%
Goodwill 1.8B USD +5.82%
Other Assets, Noncurrent 75.2M USD -1.12%
Assets 12.3B USD +9.39%
Accounts Payable, Current 85.4M USD -22.2%
Accrued Liabilities, Current 859M USD +11.5%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 1.03B USD -34.5%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Deferred Income Tax Liabilities, Net 792M USD -5.88%
Operating Lease, Liability, Noncurrent 71.1M USD +14.9%
Other Liabilities, Noncurrent 111M USD -13%
Accumulated Other Comprehensive Income (Loss), Net of Tax -603M USD +41.7%
Retained Earnings (Accumulated Deficit) 936M USD +5.87%
Stockholders' Equity Attributable to Parent 4.17B USD +19.5%
Liabilities and Equity 12.3B USD +9.39%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 267M USD -16.7%
Net Cash Provided by (Used in) Financing Activities -56.6M USD -89.8%
Net Cash Provided by (Used in) Investing Activities -272M USD -5539%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 62.3M shares -1.52%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -62.9M USD -122%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.22B USD +66.1%
Deferred Tax Assets, Valuation Allowance 312M USD +33.1%
Deferred Tax Assets, Gross 1.33B USD +14.5%
Operating Lease, Liability 78.2M USD -10.5%
Depreciation 7.65M USD +1.04%
Payments to Acquire Property, Plant, and Equipment 6.9M USD +80.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 895M USD +35.2%
Lessee, Operating Lease, Liability, to be Paid 90.4M USD -12%
Operating Lease, Liability, Current 19M USD +22.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 16.9M USD -21.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 22.8M USD +19.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Deferred Income Tax Expense (Benefit) -66.4M USD -0.49%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 12.2M USD -20.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 14.2M USD -3.56%
Deferred Tax Assets, Operating Loss Carryforwards 296M USD +12.6%
Unrecognized Tax Benefits 123M USD -14.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 12.7M USD -0.36%
Amortization of Intangible Assets 620M USD +4.35%
Deferred Tax Assets, Net of Valuation Allowance 1.02B USD +9.8%
Share-based Payment Arrangement, Expense 231M USD -1.98%